

IN THE SPECIFICATION:

Please insert the following sentence below the title and before the first paragraph on page 1 of the application:

This application is a continuation of U.S. application no. 09/512,082 filed February 24, 2000, which is a Continuation-in-Part of U.S. application no: 09/075,338, filed May 11, 1998, which is a Continuation-in-Part of U.S. application no: 09/300,425, filed April 28, 1999, both of which are herein incorporated by reference in their entirety.

Please replace the paragraph beginning on page 14, line 2, as follows:

Fig. 6 shows amino acid sequence of L19 (VH, linker and VL, SEQ ID NOS. 19-21, respectively).

Please replace the paragraph beginning at page 15, line 1 to line 11 as follows:

Residues subject to random mutation are Vk CDR3 positions 91, 93, 94 and 96 (yellow), and VH CDR3 positions 95, 96, 97, and 98 (blue). The C β atoms of these side chains are shown in darker colours. Also shown (in grey), are the residues of CDR1 and CDR2, which can be mutated to improve antibody affinity. Using the program RasMol, which can be found on the World Wide Web at chemistry.ucsc.edu/wipke/teaching/rasmol.html, (<http://www.chemistry.ucsc.edu/wipke/teaching/rasmol.html>), the structure of scFv were modeled from pdb file 1igm (Brookhaven Protein Data Bank; which can be found on the World Wide Web at [ebi.ac.uk/pcserv/pdbdb.htm](http://www.ebi.ac.uk/pcserv/pdbdb.htm)). (b) PCR amplification and library cloning strategy. The DP47 and DPK22 germline templates were modified (see text) to generate mutations in the CDR3 regions. Genes are indicated as rectangles, and CDRs as numbered boxes within the rectangle. The VH and the VL segments were then assembled and cloned in pDN332 phagemid vector.

Please replace the paragraph at page 19, lines 25-28 as follows:

NotI D D D S D D D Y K D D
 5' - GCG GCC GCA GAT GAC GAT TCC GAC GAT GAC TAC AAG GAC GAC

Please delete the paragraph beginning with Table 1 on page 34 and replace it with the following rewritten Table:

Table 1:

Sequences of selected anti-ED-B antibody clones

		VH chain			VL chain		
Clone	31-33*	50-54*	95-98*	32*	50*	91-96*	
A2	SYA	AISGSG (SEQ ID NO. 27)	GLSI (SEQ ID NO. 29)	Y	G	NGWYPW (SEQ ID NO. 32)	
G4	SYA	AISGSG (SEQ ID NO. 27)	SFSF (SEQ ID NO. 30)	Y	G	GGWLPPY (SEQ ID NO. 33)	
E1	SYA	AISGSG (SEQ ID NO. 27)	PPFY <u>PPFY</u> (SEQ ID NO. 31)	Y	G	TGRIPP (SEQ ID NO. 34)	
H10	SFS	SIRGSS (SEQ ID NO. 28)	PPFY <u>PPFY</u> (SEQ ID NO. 31)	Y	G	TGRIPP (SEQ ID NO. 34)	
L19	SPS	SIRGSS (SEQ ID NO. 28)	PPFY <u>PPFY</u> (SEQ ID NO. 31)	Y	Y	TGRIPP (SEQ ID NO. 34)	